

Dated: March 4, 2002.

**Nathan Stinson, Jr.,**

*Deputy Assistant Secretary for Minority Health.*

[FR Doc. 02-5511 Filed 3-7-02; 8:45 am]

BILLING CODE 4150-29-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Vaccines and Diagnostic Tests for Cat Scratch Fever

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are:

*Title:* Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by *Rochalimaea henselae*.

U.S. Patent Application Serial No. 07/822,539.

*Filing Date:* 01/17/92.

*Domestic Status:* Patent No.:

5,399,485.

*Issue Date:* 03/21/95.

*Title:* Methods and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/245,294.

*Filing Date:* 05/18/94.

*Domestic Status:* Patent No.:

5,644,047.

*Issue Date:* 07/01/97.

*Title:* Nucleic acids specific for *Rochalimaea quintana*.

U.S. Patent Application Serial No. 08/474,499.

*Filing Date:* 06/07/95.

*Domestic Status:* Patent No.:

5,693,776.

*Issue Date:* 12/02/97.

*Title:* Nucleic acids of *Rochalimaea henselae* and methods and compositions

for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/307,279.

*Filing Date:* 09/16/94.

*Domestic Status:* Patent No.:

5,736,347.

*Issue Date:* 04/07/98.

*Title:* Composition to protect a mammal against *Bartonella henselae* infection.

U.S. Patent Application Serial No. 08/922,970.

*Filing Date:* 09/03/97.

*Domestic Status:* Patent No.:

5,958,414.

*Issue Date:* 09/28/99.

*Title:* Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,904.

*Filing Date:* 06/07/95.

*Title:* Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 08/480,849.

*Filing Date:* 06/07/95.

*Title:* Methods and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 08/472,934.

*Filing Date:* 06/07/95.

*Title:* Nucleic Acids of *Rochalimaea Henselae* and Compositions for Diagnosing *Rochalimaea Henselae* and *Rochalimaea Quintana* Infection.

U.S. Patent Application Serial No. 09/525,310.

*Filing Date:* 03/14/00.

*Title:* Nucleic acids of *Rochalimaea henselae* and compositions for diagnosing *Rochalimaea henselae* and *Rochalimaea quintana* infection.

U.S. Patent Application Serial No. 09/752,385.

*Filing Date:* 12/29/00.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Cat scratch fever or bacillary angiomatosis is a bacterial disease transmitted via a cat scratch or bite. A previously unidentified, pathogenic species of *Bartonella* (formerly *Rochalimaea*), *B. henselae*, has been identified as the primary causative agent. A related species, *B. quintana*, may also produce illness in immunocompromised individuals. This invention identifies immunogenic peptides useful for identification of *B. henselae* and diagnosis of bacillary angiomatosis and a method of vaccinating against bacillary angiomatosis.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 4, 2002.

**Joseph R. Carter,**

*Associate Director for Management and Operations, Centers for Disease Control and Prevention.*

[FR Doc. 02-5567 Filed 3-7-02; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Growing *Ehrlichia* Species in a Continuous Cell Line

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (HHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Intervet Inc. (Intervet) having a place of business in Millsboro, Delaware. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are:

*Title:* Growing Ehrlichia Species in a Continuous Cell Line U.S. Patent Application Serial No. 07/518,182.

*Filing Date:* 05/03/90.

*Domestic Status:* Patent No.: 5,192,679.

*Issue Date:* 03/09/93.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Ehrlichiosis is a non-communicable, rarely fatal, rickettsial disease found in the United States. It is clinically similar to Rocky Mountain Spotted Fever but lacks the distinctive rash and is related to Sennetsu Fever, found only in Japan. In the United States ehrlichiosis is caused primarily by *E. Chaffeensis*. The development of diagnostics and vaccines for these diseases has been hampered by a lack of continuous cell lines to produce large quantities of Ehrlichia antigens. In this invention, a method of growing pathogenic Ehrlichia species in the continuous monocyte-macrophage cell line DH82 has been developed.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 4, 2002.

**Joseph R. Carter,**

*Associate Director for Management and Operations, Centers for Disease Control and Prevention.*

[FR Doc. 02-5568 Filed 3-7-02; 8:45 am]

**BILLING CODE 4163-18-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel, 02-36, Review of R01s and Applicant Interview.

*Date:* April 11-12, 2002.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crystal City Courtyard by Marriott, 2899 Jefferson Davis Highway, Arlington, VA 22202.

*Contact Person:* Anna Sandberg, MPH, DRPH, Scientific Review Administrator, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Building, Rm. 4AN44F, Bethesda, MD 20892, (301) 594-3089.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel, 02-61, Review of R44 Grants.

*Date:* April 12, 2002.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Philip Washko, PHD, DMD, Scientific Review Administrator, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel, 02-40, Review of R01s and Applicant Interview.

*Date:* April 17-19, 2002.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Anna Sandberg, MPH, DRPH, Scientific Review Administrator, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Building, Rm.

4AN44F, Bethesda, MD 20892, (301) 594-3089.

*Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel, 02-41, Review of R13 Grants.

*Date:* April 17, 2002.

*Time:* 3 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 45 Center Drive, Natcher Bldg., Conf. Rms. A & D, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* H. George Hausch, PHD, Acting Director, 4500 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: March 4, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-5649 Filed 3-7-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Environmental Health Sciences; Notice of Closed Meetings.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Environment Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

*Date:* April 2, 2002.

*Time:* 1 p.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* NIEHS—East Campus, 79 TW Alexander Drive, Building 4401, Room 3446, Research Triangle Park, NC 27709, (Telephone Conference Call).

*Contact Person:* RoseAnne M McGee, BS, Associated Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research